How Effective Are COVID-19 Booster Shots Against New Variants? CDC Explains

The Centers for Disease Control and Prevention issued updated recommendations in June 2024 that call for COVID-19 vaccine boosters for everyone aged 6 months and older. These shots target the XBB.1.5 lineage and related Omicron subvariants now in circulation. Data from regulatory reviews and observational studies indicate that the updated formulations restore antibody responses and lower the risk of severe outcomes, though protection against milder infection declines over months. Public health agencies continue to track how well these boosters hold up as the virus changes.

Who is eligible for COVID-19 vaccine boosters under CDC guidance?

CDC guidance states that all people 6 months and older should receive an updated 2023-2024 COVID-19 vaccine. [1] The policy covers both previously vaccinated individuals and those who have never received a dose.

How do the updated boosters perform against currently circulating SARS-CoV-2 variants?

Early data reviewed by the Food and Drug Administration show that the XBB.1.5-targeted monovalent shots increase neutralizing antibodies against the dominant Omicron family members. [2] Real-world estimates link these boosters to reduced rates of symptomatic illness and hospitalization in the initial months after administration.

What real-world data exists on the effectiveness of COVID-19 boosters against symptomatic and severe disease?

An MMWR analysis of the IVY Network across 18 states found that bivalent boosters lowered COVID-19-associated hospitalization risk during the period when Omicron subvariants circulated. [3] Protection against severe disease remained higher than protection against infection alone.

Is there evidence of waning immunity following booster doses?

The same MMWR report documented that effectiveness against infection falls several months after the dose, with a steeper drop in older adults. [3] Protection against hospitalization stayed more stable during the first three to six months.

Are additional booster updates expected if new variants emerge?

Surveillance systems at the CDC and FDA monitor variant emergence and will inform future formulation changes if needed. [1] [2] No fixed schedule for additional updates has been set.

What this means

Current authorizations and effectiveness estimates describe a pattern in which boosters extend defense against serious illness from present strains, yet the degree of that defense narrows with time and with any further viral shifts.

Key takeaways

CDC guidance from June 2024 recommends an updated COVID-19 vaccine for everyone 6 months and older. [1]
Updated XBB.1.5 monovalent shots raised antibody levels against circulating Omicron subvariants in immunogenicity assessments. [2]
Observational data from the IVY Network linked recent boosters to lower hospitalization rates through April 2023. [3]
Effectiveness against infection wanes within months, while protection from severe disease holds longer in the initial post-booster window. [3]
Ongoing variant monitoring may prompt future changes to vaccine composition.

Limitations

Estimates come from periods before some newer subvariants became widespread, and observational designs carry risks of confounding. Guidance can shift if additional data alter the risk picture.

Last updated: September 3, 2026